Modality
mRNA
MOA
Anti-Aβ
Target
Tau
Pathway
Innate Imm
CRC
Development Pipeline
Preclinical
~Jan 2015
→ ~Apr 2016
Phase 1
~Jul 2016
→ ~Oct 2017
Phase 2
Jan 2018
→ Mar 2030
Phase 2Current
NCT04153089
1,244 pts·CRC
2018-01→2030-03·Active
NCT06856582
1,958 pts·CRC
2024-08→2028-11·Active
3,202 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-12-148mo awayPh1 Dose Esc· CRC
2028-11-092.6y awayPh2 Data· CRC
2030-03-214.0y awayPh2 Data· CRC
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P2
Active
P2
Active
Catalysts
Ph1 Dose Esc
2026-12-14 · 8mo away
CRC
Ph2 Data
2028-11-09 · 2.6y away
CRC
Ph2 Data
2030-03-21 · 4.0y away
CRC
Active|StartCompletionToday
Trials (2)
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8369 | Eli Lilly | Approved | Menin | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| RLA-6817 | Relay Therapeutics | Phase 3 | TIGIT | |
| Lisoosocimab | Zealand Pharma | Approved | KIF18A | |
| PRA-419 | Praxis Precision | Approved | Cl18.2 |